These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 32883119)

  • 21. Diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States: Recommendations from a panel of experts.
    Karam C; Mauermann ML; Gonzalez-Duarte A; Kaku MC; Ajroud-Driss S; Brannagan TH; Polydefkis M
    Muscle Nerve; 2024 Mar; 69(3):273-287. PubMed ID: 38174864
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy.
    Maestro-Benedicto A; Vela P; de Frutos F; Mora N; Pomares A; Gonzalez-Vioque E; Briceño A; Cabrera E; Cobo-Marcos M; Dominguez F; Gonzalez-Lopez E; Segovia J; Lara-Pezzi E; Garcia-Pavia P
    Eur J Heart Fail; 2022 Dec; 24(12):2367-2373. PubMed ID: 35999650
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Red flags and adjusted suspicion index for distinguishing hereditary transthyretin amyloid polyneuropathy from idiopathic axonal polyneuropathy.
    Warendorf JK; van der Star GM; Dooijes D; Notermans NC; Vrancken AFJE
    Neurol Sci; 2023 Oct; 44(10):3679-3685. PubMed ID: 37266816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The neuropathy in hereditary transthyretin amyloidosis: A narrative review.
    Tozza S; Severi D; Spina E; Iovino A; Aruta F; Ruggiero L; Dubbioso R; Iodice R; Nolano M; Manganelli F
    J Peripher Nerv Syst; 2021 Jun; 26(2):155-159. PubMed ID: 33960565
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world outcomes in non-endemic hereditary transthyretin amyloidosis with polyneuropathy: a 20-year German single-referral centre experience.
    Ungerer MN; Hund E; Purrucker JC; Huber L; Kimmich C; Aus dem Siepen F; Hein S; Kristen AV; Hinderhofer K; Kollmer J; Schönland S; Hegenbart U; Weiler M
    Amyloid; 2021 Jun; 28(2):91-99. PubMed ID: 33283548
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Amyloid Neuropathy: From Pathophysiology to Treatment in Light-Chain Amyloidosis and Hereditary Transthyretin Amyloidosis.
    Chompoopong P; Mauermann ML; Siddiqi H; Peltier A
    Ann Neurol; 2024 Sep; 96(3):423-440. PubMed ID: 38923548
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Same same, but different? The neurological presentation of wildtype transthyretin (ATTRwt) amyloidosis.
    Kleefeld F; Scherret E; Knebel F; Messroghli D; Heidecker B; Wetz C; Schatka I; Barzen G; Tschöpe C; Amthauer H; Hahn K
    Amyloid; 2022 Jun; 29(2):92-101. PubMed ID: 34994254
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A natural history analysis of asymptomatic
    Coelho T; Conceição I; Waddington-Cruz M; Keohane D; Sultan MB; Chapman D; Amass L;
    Amyloid; 2022 Dec; 29(4):228-236. PubMed ID: 35730447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Description of a large cohort of Caucasian patients with V122I ATTRv amyloidosis: Neurological and cardiological features.
    Gentile L; Di Bella G; Minutoli F; Cucinotta F; Obici L; Mussinelli R; Arimatea I; Russo M; Toscano A; Vita G; Mazzeo A
    J Peripher Nerv Syst; 2020 Sep; 25(3):273-278. PubMed ID: 32395865
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neurological manifestations of hereditary transthyretin amyloidosis: a focus on diagnostic delays.
    Kaku MC; Bhadola S; Berk JL; Sanchorawala V; Connors LH; Lau KHV
    Amyloid; 2022 Sep; 29(3):184-189. PubMed ID: 35253562
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A mini-review of Vutrisiran and Eplontersen in hereditary transthyretin-mediated amyloidosis with polyneuropathy.
    Olatunji G; Kokori E; Abraham IC; Omoworare O; Olatunji D; Ezeano C; Emmanuel Adeoba B; Stanley AC; Oluwatobiloba AM; Oluwademilade OB; Shimelis KM; Olanisa O; Aderinto N
    Medicine (Baltimore); 2024 Jun; 103(26):e38767. PubMed ID: 38941378
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sex-Related Risk of Cardiac Involvement in Hereditary Transthyretin Amyloidosis: Insights From THAOS.
    Caponetti AG; Rapezzi C; Gagliardi C; Milandri A; Dispenzieri A; Kristen AV; Wixner J; Maurer MS; Garcia-Pavia P; Tournev I; Planté-Bordeneuve V; Chapman D; Amass L;
    JACC Heart Fail; 2021 Oct; 9(10):736-746. PubMed ID: 34391735
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Magnetic resonance neurography and diffusion tensor imaging of the sciatic nerve in hereditary transthyretin amyloidosis polyneuropathy.
    Gasparotti R; Salvalaggio A; Corbo D; Agazzi G; Cacciavillani M; Lozza A; Fenu S; De Vigili G; Tagliapietra M; Fabrizi GM; Pareyson D; Obici L; Briani C
    J Neurol; 2023 Oct; 270(10):4827-4840. PubMed ID: 37329346
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Neurological manifestations of ATTR amyloidosis].
    Pernice HF; Hahn K
    Inn Med (Heidelb); 2023 Sep; 64(9):848-854. PubMed ID: 37555967
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neurofilament light chain as a disease severity biomarker in ATTRv: data from a single-centre experience.
    Luigetti M; Di Paolantonio A; Guglielmino V; Romano A; Rossi S; Sabino A; Servidei S; Sabatelli M; Primiano G
    Neurol Sci; 2022 Apr; 43(4):2845-2848. PubMed ID: 35094171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 3-T MR neurography of lumbo-sacral plexus in hereditary transthyretin-related amyloidosis with polyneuropathy.
    Hodel J; Benadjaoud S; Benadjaoud MA; Lefaucheur JP; Planté-Bordeneuve V
    Eur Radiol; 2022 Nov; 32(11):7865-7871. PubMed ID: 35438324
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hereditary transthyretin amyloidosis overview.
    Manganelli F; Fabrizi GM; Luigetti M; Mandich P; Mazzeo A; Pareyson D
    Neurol Sci; 2022 Dec; 43(Suppl 2):595-604. PubMed ID: 33188616
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathological spectrum of hereditary transthyretin renal amyloidosis and clinicopathologic correlation: a French observational study.
    Dang J; Ferlicot S; Misrahi M; Mussini C; Kounis I; Rémy P; Samuel D; Planté-Bordeneuve V; Adams D; Funalot B; Snanoudj R; Damy T; Moktefi A; Audard V; Zaidan M
    Nephrol Dial Transplant; 2023 Aug; 38(9):2019-2030. PubMed ID: 36646436
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hereditary Transthyretin Amyloidosis and the Impact of Classic and New Treatments on Kidney Function: A Review.
    Meléndrez-Balcázar E; Aranda-Vela K; Cervantes-Hernández A; López-Cureño S
    Am J Kidney Dis; 2024 Aug; 84(2):224-231. PubMed ID: 38484868
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emerging multisystem biomarkers in hereditary transthyretin amyloidosis: a pilot study.
    Luigetti M; Vitali F; Romano A; Sciarrone MA; Guglielmino V; Ardito M; Sabino A; Servidei S; Piro G; Carbone C; Graziani F; Lillo R; Ferraro PM; Primiano G
    Sci Rep; 2024 Aug; 14(1):18281. PubMed ID: 39112608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.